"Antidepressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.
| Descriptor ID |
D000928
|
| MeSH Number(s) |
D27.505.954.427.700.122
|
| Concept/Terms |
Antidepressive Agents- Antidepressive Agents
- Agents, Antidepressive
- Antidepressant Drugs
- Drugs, Antidepressant
- Antidepressants
|
Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents".
This graph shows the total number of publications written about "Antidepressive Agents" by people in this website by year, and whether "Antidepressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 3 | 4 |
| 1996 | 2 | 1 | 3 |
| 1997 | 5 | 0 | 5 |
| 1998 | 3 | 0 | 3 |
| 1999 | 0 | 3 | 3 |
| 2000 | 2 | 1 | 3 |
| 2002 | 4 | 0 | 4 |
| 2003 | 3 | 1 | 4 |
| 2004 | 6 | 2 | 8 |
| 2005 | 3 | 3 | 6 |
| 2006 | 3 | 5 | 8 |
| 2007 | 7 | 1 | 8 |
| 2008 | 4 | 1 | 5 |
| 2009 | 3 | 3 | 6 |
| 2010 | 6 | 3 | 9 |
| 2011 | 7 | 4 | 11 |
| 2012 | 6 | 1 | 7 |
| 2013 | 9 | 5 | 14 |
| 2014 | 5 | 1 | 6 |
| 2015 | 5 | 3 | 8 |
| 2016 | 4 | 2 | 6 |
| 2017 | 7 | 2 | 9 |
| 2018 | 5 | 3 | 8 |
| 2019 | 3 | 4 | 7 |
| 2020 | 5 | 4 | 9 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 4 | 5 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antidepressive Agents" by people in Profiles.
-
Carter E, Banerjee S, Alexopoulos GS, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ. Prediction of remission of pharmacologically treated psychotic depression: A machine learning approach. J Affect Disord. 2025 Jul 15; 381:291-297.
-
Ihaddadene RA, Alexopoulos GS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ, Bingham KS. Predictors of attrition during acute pharmacotherapy of psychotic depression in a clinical trial. Psychiatry Res. 2024 Dec; 342:116192.
-
Rothschild AJ. Question: How Should I Switch From One Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) to Another SSRI or SNRI in a Patient With Major Depressive Disorder? J Clin Psychopharmacol. 2024 Sep-Oct 01; 44(5):531-532.
-
Andrews P, Vega JN, Szymkowicz SM, Newhouse P, Tyndale R, Elson D, Kang H, Siddiqi S, Tyner EB, Mather K, Gunning FM, Taylor WD. Effects of open-label transdermal nicotine antidepressant augmentation on affective symptoms and executive function in late-life depression. J Affect Disord. 2024 Oct 01; 362:416-424.
-
Cintr?n Pastrana MA, Irizarry Flores JC, Rothschild AJ. Challenges in the Treatment of Psychotic Bipolar Depression. J Clin Psychopharmacol. 2024 Jul-Aug 01; 44(4):407-412.
-
Boama-Nyarko E, Flahive J, Zimmermann M, Allison JJ, Person S, Moore Simas TA, Byatt N. Examining racial/ethnic inequities in treatment participation among perinatal individuals with depression. Gen Hosp Psychiatry. 2024 May-Jun; 88:23-29.
-
Carlini SV, Osborne LM, Deligiannidis KM. Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression. Dialogues Clin Neurosci. 2023 12; 25(1):92-100.
-
Deligiannidis KM, Clayton AH. Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD. J Clin Psychiatry. 2023 03 16; 84(Suppl 1).
-
Yang Q, Lagerberg T, Sj?lander A, Bertone-Johnson ER, Fang F, Ye W, Chang Z, Valdimarsd?ttir UA, Lu D. Use of hormonal contraceptives and antidepressants and risks of suicidal behavior and accidents among women with premenstrual disorders: a nationwide cohort study. BMC Med. 2022 12 15; 20(1):482.
-
Fabrizio VA, Lindsay CV, Wilcox M, Hong S, Lynn T, Norwitz ER, Yonkers KA, Abrahams VM. The serotonin reuptake inhibitor fluoxetine induces human fetal membrane sterile inflammation through p38 MAPK activation. J Reprod Immunol. 2023 02; 155:103786.